Implanet's Squale anterior cervical cage gets FDA clearance

Apr. 11, 2023 5:10 AM ETImplanet S.A. (IMPZY)By: Ravikash, SA News Editor

French medical device maker Implanet (OTC:IMPZY) said that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to its Squale anterior cervical cage.
The Squale, from the OSD product portfolio, features a range of implants, a design adapted to vertebral anatomy and radiolucent for radiographic confirmation of interbody fusion, according to the company.
Implanet noted that to date, more than 15K Squale cages have been implanted globally.
The company said that the FDA clearance follows the first surgeries in the U.S. in 2022 with the ORIGIN cervical plate, which marked the first successful collaboration between Implanet and OSD.
"The Implanet America sales teams should be able to launch the marketing of this anterior cervical cage range before the summer of 2023," said Implanet CEO Ludovic Lastennet.